$24.2MSeed, 8 January 2026
Seed round to move two drug candidates for autoimmune and inflammatory diseases toward preclinical stage.
- Amount
- $24.2M
- Stage
- Seed
- Announced
- 8 January 2026
- Lead
- Elaia
- Other investors
- Pfizer Ventures, Bpifrance (InnoBio), Wallonie Entreprendre, Argobio Studio, MACSF, Institut Pasteur, InvestSud, Sambrinvest, Mission BioCapital
- Use of funds
- Seed round to move two drug candidates for autoimmune and inflammatory diseases toward preclinical stage.
- Checked
- Announced by the company
- Sources
- Enodia Therapeutics raises EUR 20.7M for its SEC61 small-molecule platform businesswire.com
Enodia Therapeutics raises EUR 20.7M for its SEC61 small-molecule platform zonebourse.com